Here’s what you should know:
1. The company tested a once-daily oral pill of antiemetic drug ondansetron in 127 subjects across 16 U.S. clinical sites.
2. RedHill Biopharma expects to report results of its trial in September 2017.
3. The company believes the treatment has the “potential to be a preferred once-daily treatment” for IBS-D patients.
More articles on gastroenterology:
GI center to know: Arizona Digestive Health
A regional breakdown of multispecialty ASC caseloads — GI makes up what %?
GI leader to know: Dr. David Landy of Birmingham Gastroenterology
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
